Evidence map›Paper›PMID 27566569›Full record

ArticleOncotarget2016

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.

Shang-Yi Huang, Hsiu-Hsia Lin, Chung-Wu Lin, Chi-Cheng Li, Ming Yao, Jih-Luh Tang, Hsin-An Hou, Woei Tsay, Sheng-Je Chou, Chieh-Lung Cheng and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. PD-L1Biomarker research · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Immunotherapy and predictive immunologic profile: the tip of the iceberg.Medical oncology (Northwood, London, England) · 2021
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shang-Yi HuangDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Hsiu-Hsia LinDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Chung-Wu LinDepartment of Pathology, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Chi-Cheng LiTai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Ming YaoDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Jih-Luh TangDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Hsin-An HouDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Woei TsayDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Sheng-Je ChouDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Chieh-Lung ChengDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
Hwei-Fang TienDepartment of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
National Taiwan University Hospital · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous hematopoietic stem cell transplantation (AuHSCT) is standard in treating eligible multiple myeloma (MM) patients. However, the outcome after treatment is highly variable. We used ELISA to analyze the levels of soluble PD-L1 (suPD-L1) in bone marrow (BM) plasma from 61 patients with MM at 100 days after AuHSCT. Patients were classified into high (H) and normal-to-low (NL) groups depending on their suPD-L1 levels. Among patients who had a very good partial response (VGPR) or better after AuHSCT, those in the H-group had a shorter response period (RpSCT) as well as shorter overall survival (OS) than those in the NL-group. Multivariate analyses confirmed that a high suPD-L1 level and high-risk cytogenetic abnormalities are independent factors for RpSCT. Our data suggest that suPD-L1 in the BM plasma of MM patients who have VGPR or better after AuHSCT could be used as a biomarker to predict outcome.

Indexed as

AdolescentAdultAgedB7-H1 AntigenBiomarkers, TumorBone MarrowCD8-Positive T-LymphocytesDisease-Free SurvivalDisease ProgressionEnzyme-Linked Immunosorbent AssayFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedMultiple MyelomaB7-H1 AntigenBiomarkers, TumorCD274 protein, humanautologous transplantationbone marrow plasmamultiple myelomaprognosissoluble PD-L1

Identifiers

PMID27566569
PMCPMC5308741
OpenAlexW2513838373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.